MRgHIFU Thalamotomy Held Its Own in Older Essential Tremor Patients
Magnetic resonance guided high intensity focused ultrasound thalamotomy continues to move from specialized option to a more mainstream procedural choice for essential tremor, especially for patients who are poor candidates for open surgery or deep brain stimulation. This preprint adds a practical question to the discussion: does the procedure remain safe and effective in older adults and in patients carrying medical comorbidities that often complicate procedural decision-making?
At Parkview Regional Medical Center, investigators reviewed EPIC electronic medical records for patients who underwent MRgHIFU from January 2023 through November 2025. The cohort included 68 patients, with tremor severity tracked using the Clinical Rating Scale for Tremor and quality of life tracked using the Quality of life in ET Questionnaire. Side effects reported after the procedure were also captured, giving the analysis both efficacy and safety dimensions rather than a narrow symptom snapshot.
The central finding was straightforward. CRST and QUEST scores improved up to 1 year from baseline across the cohort, and early efficacy in older patients, defined as those 70 years and older, was not statistically different from that seen in younger patients through 3 months after treatment.
Tremor Control Was Preserved Across Age Groups
For a neurologic disorder defined by action tremor, the value of a procedure lies in whether it reduces involuntary movement enough to change how patients write, eat, drink, and perform other daily tasks. The data here suggest that age alone did not blunt the early benefit of MRgHIFU. In practical terms, older patients appeared to derive the same near-term symptomatic improvement as younger adults, which matters because age is often the factor that pushes clinicians toward hesitation when discussing invasive therapies.
The biological logic fits the intervention. MRgHIFU targets the thalamus, disrupting the tremor circuit without an incision or implanted hardware. By modulating the pathway that relays tremor signals, the treatment can reduce the oscillatory motor output that drives functional impairment in essential tremor. In older adults, where frailty and cumulative disease burden can narrow procedural options, a noninvasive lesioning approach carries obvious appeal if safety holds up.
One sentence captures the clinical weight of the result: age did not erase benefit.
The cohort’s quality-of-life trajectory reinforces that point. Improvement in QUEST scores through 1 year suggests patients were not only scoring better on tremor metrics but also experiencing changes large enough to register in daily function and perceived burden. For a disorder that can steadily erode independence, that dual movement in symptom severity and life quality is the kind of signal clinicians look for when deciding whether a therapy is more than a technical success.
Comorbidities Did Not Erode the Treatment Signal
Comorbidity analysis is where this preprint becomes especially relevant to real-world practice. Many essential tremor patients are older and arrive with pulmonary disease, cardiovascular disease, diabetes, or a family history of tremor layered into the same chart. Instead of treating these as reasons to exclude patients from analysis, the study examined whether they altered recovery or response.
The pattern was reassuring. Effects of comorbidities on CRST or QUEST improvement were transient or did not affect the primary endpoints. In other words, baseline medical complexity did not appear to wipe out the symptomatic gain achieved by MRgHIFU. That matters because procedural counseling for essential tremor frequently hinges on whether the patient can tolerate anesthesia, surgery, or device implantation. A treatment that preserves efficacy in medically complex patients fills an important niche.
A single caveat remains embedded in the data: this was not an equivalence trial, and the size of the cohort limits how finely it can separate truly similar outcomes from outcomes that simply failed to reach statistical separation.
Safety Signals Were Small but Worth Reading Closely
Safety findings were not dominated by severe adverse events in the abstract, but the side effect analysis deserves careful attention because even mild neurological or systemic symptoms can influence whether a patient views the procedure as worthwhile. Older patients showed fewer total side effects at 3 months, with the values reported as 1.17 versus 0.21 and a p value of 0.017. Patients with pulmonary disease showed fewer side effects at 1 month, with values of 1.9 versus 1.1 and a p value of 0.036. Patients with a family history of tremor showed more side effects at day 1, with values of 1.5 versus 2.5 and a p value of 0.025.
These differences are interesting, but they do not point in a single mechanistic direction. The older-adult and pulmonary-disease findings may reflect selection effects, differences in symptom reporting, or variability in who was eligible for follow-up rather than a direct physiologic protective effect. The family-history signal may similarly represent a subgroup with different baseline tremor characteristics or heightened awareness of post-procedure symptoms. None of those possibilities can be resolved from the abstract alone.
Still, the overall safety conclusion is clear enough for a preprint: age and comorbidities were not detected to adversely affect safety or efficacy after MRgHIFU in this ET cohort.
What This Means for Procedural Counseling
MRgHIFU has been attractive because it can treat a disabling movement disorder without the burden of implanted hardware, staged programming, or a craniotomy. For older adults, that procedural profile is especially relevant. Many patients with essential tremor are not merely elderly; they are elderly with medical complexity, which is exactly the population where a minimally invasive, image-guided option can shift the balance between living with tremor and pursuing intervention.
The findings support a more inclusive view of candidacy, at least in the short term. They suggest that clinicians should not assume older age or common comorbidities automatically predict worse tremor control after thalamotomy. The study also strengthens the case for shared decision-making grounded in symptom burden rather than age alone, since the functional payoff appears to persist across the subgroups examined.
Even so, the evidence remains early. The analysis was retrospective, limited to a single health system, and based on 68 patients. Follow-up beyond the time points described in the abstract is not available here, and the subgroup comparisons should be read as hypothesis-generating rather than definitive. Larger cohorts will be needed to determine whether the same pattern holds when more patients, more centers, and more prolonged follow-up are brought into view.
For now, the message is practical and restrained: MRgHIFU thalamotomy appears to deliver meaningful tremor relief and quality-of-life improvement without an obvious penalty in older adults or patients with comorbid illness, but the sample is still too small to settle questions of equivalence or long-term durability.